Quoin Pharmaceuticals Cements Leadership Position in Rare Diseases with New Research Agreement

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company focused on rare and orphan diseases, announced a research agreement with The School of Pharmacy at University College Cork (UCC) in Ireland. This collaboration, aimed at developing innovative topical formulations of rapamycin (sirolimus), marks a strategic step towards potentially expanding the company’s treatment pipeline for a variety of rare and orphan diseases that currently lack approved therapies.

The partnership will utilize UCC’s advanced dissolvable microneedles technology and other novel formulation approaches to enhance the local delivery of rapamycin, improving its therapeutic effectiveness while offering a painless and minimally invasive delivery method that minimizes infection risk and simplifies disposal.

Under the terms of the agreement, Quoin will fund a research program at UCC to develop several topical rapamycin formulations. Should the research prove successful, Quoin will have the option to continue development and potentially move these formulations into clinical trials. This agreement does not involve any upfront licensing fees, milestone payments, or royalties on future product sales.

Dr. Michael Myers, CEO of Quoin, stated, “The School of Pharmacy at UCC has a very strong track record in the design of dermal drug delivery technologies, with a particular focus on dissolvable microneedles. We are very pleased and excited to announce the signing of this research agreement, and we believe this partnership with UCC could ultimately lead to the development of proprietary topical rapamycin formulations, which Quoin would have the option to assess clinically as potential treatments for a number of rare and orphan diseases.”

Rapamycin is an immunosuppressive drug that inhibits the mTOR signaling pathway and has potential for treating various rare diseases. Its delivery has been challenging due to its molecular size and poor solubility. UCC’s microneedle technology, which uses biodegradable materials that dissolve upon skin contact to release the drug directly into the dermal layers, aims to address these challenges, offering a method that enhances patient comfort and reduces skin trauma, particularly important in treatments for skin-related rare diseases.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others.



This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Quoin Pharmaceuticals Cements Leadership Position in Rare Diseases with New Research Agreement

Catie Corcoran

Biotech Editor